-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nivolumab combined with ipilmumab has been approved by the Scottish Medicines Federation (SMC) as a treatment option for adult patients for the treatment of patients who have failed previous fluoropyrimidine-based chemotherapy
Recently, Bristol-Myers Squibb (BMS) announced that the Scottish Pharmaceutical Union (SMC) has accepted Nivolumab in combination with ipilmumab as a late mismatch repair defect (dMMR) or high microsatellite instability (MSIH)Treatment options for adults with colorectal cancer , these patients have failed previous fluoropyrimidine-based chemotherapy, and the therapy is used by the NHS in Scotland
Colorectal cancer
This group of patients is characterized by a rare genetic mutation called MSI-H or dMMR, which affects how the cancer grows
diagnosis
The median age of the treated patients was 66 years (N = 45)
The objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://